Tristan Cesar Mañalac’s Post

Pfizer's lung cancer drug Lorbrena shows promising results in extending the lifespan of patients with a rare form of the disease. Recent research reveals that the drug, targeting ALK-positive non-small cell lung cancer, can significantly improve outcomes. This type of cancer affects younger nonsmoking individuals and is known for its aggressive nature, particularly its tendency to spread to the brain early on. After five years, the research shows that 60% of patients on Lorbrena were still alive, contrasting with only 8% of those on a different drug, crizotinib. Additionally, patients on Lorbrena were nearly 95% less likely to experience brain metastasis compared to those on crizotinib. These findings mark a significant advancement in the treatment of ALK-positive lung cancer, offering hope to the over 70,000 individuals diagnosed annually with this challenging condition. #Pfizer #Lorbrena #lungcancer #medicalresearch #NSCLC #ASCO

I love this article which demonstrates the constant need for biological biospecimen analysis from patients to further fine tune their care. Basic research, Pharmaceutical research and healthcare are intricately connected. Read about how a drug used for Irritable Bowel Syndrome is found to inhibit CHRM1 which is common in prostate cancer cases resistant to chemotherapy. #BiospecimensforResearch

Another immunotherapy clinical trial failed. This time it's anti PD-L1 mAb or Durvalumab of #Astrazeneca which was tested for resectable, early stage lung cancer treatment. This is third immunooncology drugs focused trial that failed after two previous failures of Checkmate and Keynote (Merck's Keytruda). BR.31 trial failed to show disease-free survival compare to placebo treatment in NSCLC patients that had ≥ 25% PD-L1 expression on tumour cells (and EGFR/ALK mut negative). The key patient inclusion criteria was: "Complete surgical resection of the primary NSCLC with surgical margins of resection must be negative for tumour". IO pharma companies must rethink patient stratification strategies before landing empty handed despite a decade long study. #immunooncology #biotech #keytruda #merck #bms #clincialtrial #durvalumab #drugdiscovery https://lnkd.in/d4ygQAEg

ImmunityBio, Inc. declares the FDA's approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist designed for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer. This innovative immunotherapy not only stimulates the proliferation and activation of the patient’s own NK cells and CD8+ killer T cells but also initiates the activation of CD4+ T helper cells, thus enhancing the proliferation of memory killer T cells. Novel immunotherapy stands as a focal point of discussion for the upcoming 2024 Annual Conference of our society, set to convene in Cambridge, MA, USA on Saturday, May 11, 2024. We extend a warm invitation for you to join us in engaging dialogues. Registration for the conference is now open via the following link. https://lnkd.in/ecmFPA4v   #antibodydiscovery #antibodydrugconjugates #oncology #annualmeeting #annualconference #antibodies #mab #mabs #immunotherapy https://lnkd.in/gqPVRV4d).

Showcasing first-in-class PD-1/VEGF bispecific, first-in-class PD-1/CTLA-4 bispecific, and next-gen CD47 antibody across multiple solid tumor clinical studies at ESMO.

The paper discusses the development of a novel PD-1-targeted, receptor-masked IL-2 immunocytokine (PD1-IL2Ra-IL2) designed to overcome the limitations of traditional IL-2-based cancer therapies, which are often associated with severe systemic toxicities and limited anti-tumor efficacy. This strategy enhances anti-tumor immunity while minimizing systemic toxicity, a common issue with traditional IL-2 therapies. Preclinical models showed robust tumor control and reduced side effects, making this a promising approach for safer, more effective cancer immunotherapy. This paper highlight that IL-2Rα engagement is important for the anti-tumor activity of systemic IL-2 therapy. #cancer; #oncology; #immunotherapy https://lnkd.in/dg9tnvk7

Akeso will showcase promising results from 13 clinical studies on its internally developed PD-1/CTLA-4 bispecific antibody cadonilimab, PD-1/VEGF bispecific antibody ivonescimab, next-generation CD47 monoclonal antibody ligufalimab, and commercially available PD-1 monoclonal antibody penpulimab at the #ESMO Congress 2024！ These studies span advanced colorectal cancer, triple-negative breast cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, nasopharyngeal carcinoma, gynecological malignancies, gastric cancer, esophageal squamous cell carcinoma, and biliary tract malignancies. https://lnkd.in/gU7j3HB5

#transcript Dr. Steve Marcus, CEO of Cantex Pharmaceuticals,  emphasizes the importance of the RAGE receptor in diseases like cancer and inflammation.  Their lead compound, azeliragon, blocks the activation of the RAGE receptor and shows effectiveness in inhibiting cancer metastasis and enhancing the impact of radiation. Clinical trials are underway for breast cancer, pancreatic cancer, glioblastoma, and COVID-19. This approach addresses the cancer cells and the microenvironment in which they reside to reduce disease progression and alter the immune environment. #Cantex #RAGE #RAGEReceptor #Azeliragon #PancreaticCancer #Glioblastoma #Cancer cantex.com https://lnkd.in/gfiJ3Mwy

Highlights in this article How do clinicians currently treat colorectal cancer? What is ABBV-400, and how does it work? Who are the patients receiving ABBV-400 in the Phase 1 trial? How did you feel when you saw those positive results? What sort of feedback have you heard from patients? What do you plan to do next? Colorectal cancer (CRC) is one of the leading causes of global cancer deaths, with over 1.9 million annual cases (1). Traditional chemotherapies often have many drawbacks, such as limited efficacy combined with severe systemic side effects like nausea and fatigue, which impact the patient's quality of life. Antibody-drug conjugates offer an alternative therapeutic approach by combining a monoclonal antibody specific to CRC cells that ferries a potent chemotherapeutic payload directly to the tumor.

💡 Compelling Article on Antibody Drug Conjugates (ADCs) 💡 Oncologists are increasingly excited about Antibody Drug Conjugates (ADCs), a groundbreaking advancement in cancer treatment. ADCs allow for the use of more potent chemotherapy agents by attaching the drug to an antibody, delivering powerful cancer-fighting medicines directly into tumour cells. This innovative approach significantly reduces side effects and improves treatment success rates. The precision of ADCs offers new hope for more effective and targeted cancer therapies. Find out more about this exciting area of research: https://lnkd.in/egQFNMea #ADC #Therapy #CancerResearch #CancerTherapeutics